Salvatore Salamone is a scientist and researcher studying diagnostic medicine and therapeutic drug monitoring.
Education
Salamone earned two bachelor's degrees from Villanova University, a master's and a PhD degree from Rutgers University and was a Science Engineering Research Council (SERC) Post-Doctoral Fellow at the University of Oxford, UK.[1]
Career
Salamore is responsible for the development of many of the major reagents used within psychiatric drug level monitoring.[2][3] He is the founder of Saladax Biomedical, Inc.[1] His contributions to diagnostic medicine have been recognized through several local awards, including the Ben Franklin Innovation Award[4] and the New Jersey Inventors Hall of Fame in 2016.[5] Salamone has 70 FDA-approved products and more than 200 instrument applications. He is the editor of a textbook on benzodiazapines[6] and is also the holder of 41 issued US patents.[7] The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) awarded Salamone the C.E. Pippenger Award for outstanding contributions to the field of Therapeutic Drug Monitoring in 2021.[8]
References
- 1 2 "Bloomberg - Salvatore J Salamone". www.bloomberg.com. Retrieved 2020-01-15.
- ↑ Acton, Q. Ashton (2013). Schizophrenia: New Insights for the Healthcare Professional. ScholarlyEditions. p. 434. ISBN 9781481655712.
- ↑ US 8771972, Salamone, Salvatore J.; Courtney, Jodi Blake & Sard, Howard et al., "Clozapine immunoassay", published 2014-07-08, assigned to Saladax Biomedical Inc.
- ↑ "Ben Franklin Announces Innovation Award Winners". BFTP | NEP. 2009-04-17. Retrieved 2020-01-15.
- ↑ "2016 Awardees". NJ Inventors Hall of Fame 2018. Retrieved 2020-01-15.
- ↑ Salamone, Salvatore J (2001). Benzodiazepines and GHB: detection and pharmacology. Totowa, N.J.: Humana Press. ISBN 978-0-89603-981-0. OCLC 46463342.
- ↑ "Salvatore J. Salamone Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2020-01-15.
- ↑ "C.E. Pippenger Award". www.iatdmct.org. Retrieved 2022-03-17.